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Abstract. Inhibition of efflux pumps is an emerging approach in cancer therapy and drug delivery. Since
it has been discovered that polymeric pharmaceutical excipients such as Tweens\ or Pluronics\ can
inhibit efflux pumps, various other polymers have been investigated regarding their potential efflux
pump inhibitory activity. Among them are polysaccharides, polyethylene glycols and derivatives,
amphiphilic block copolymers, dendrimers and thiolated polymers. In the current review article, natural
and synthetic polymers that are capable of inhibiting efflux pumps as well as their application in cancer
therapy and drug delivery are discussed.
KEY WORDS: drugdelivery; efflux pump inhibitors; P-glycoprotein; P-gp inhibitors; polymeric inhibitors.
INTRODUCTION
Since 1976, when Juliano and Ling identified a membrane
glycoprotein to be responsible for drug resistance in colchicin
drug resistant cells and designated it BP-glycoprotein,^ the
interest of the scientific community in such transporters has
been increasing from year to year (1). Various review articles
addressing the localisation, mechanisms and nature of these
transporters have been published previously (2,3). Moreover,
many review articles discuss the role of these transporter
proteins in drug development and drug delivery (4–6). The
170 kDa P-glycoprotein (P-gp), which is located in the apical
membranes of epithelial cells, belongs to a group of
transporter proteins that are known as efflux pumps. These
ATP dependent transmembrane located transporter proteins
can actively transport a wide range of structurally diverse
compounds out of the cells; including anticancer agents (7),
immunosuppressants (8), steroid hormones (9), calcium
channel blockers (10), beta-adrenoreceptor blockers and
cardiac glycosides (11,12). They are over-expressed in cancer
cells and are responsible for the multi drug resistance (MDR)
of such cells. Besides, they are expressed in healthy tissues
including liver, placenta, the proximal tubule in the kidney,
capillary endothelial cells of brain and testis, and epithelial
cells of the intestine (2,3). In combination with other mech-
anisms, e.g., CYP3A, they act as a part of the detoxification
system and affect absorption, distribution, metabolism and
elimination (13). The encoding genes of these transporters
belong to the ATP Binding Cassette (ABC) gene family.
Apart from P-gp, other important efflux pumps are the
multidrug resistant proteins (MRP) 1 and 2 as well as the
breast cancer resistant protein (BCRP) (14).
Basically, an inhibition of efflux pumps can be applied to
(a) improve the transport of efflux pump substrate anticancer
agents into MDR cells and (b) drug delivery. The over-
expression of efflux pumps such as P-gp in tumours
consequently leads to low concentrations of anticancer agents
inside MDR cells during cancer therapy, so that therapeutic
effects are minimized or do not occur at all. To circumvent
MDR in cancer cells, researchers either focus on the
development of novel therapeutic non-substrate agents or
formulations that allow the drug to bypass efflux pump
transport (15, 16), or on auxiliary agents that can inhibit
efflux pumps (17). Regarding drug delivery, there are two
main indications for efflux pump inhibition: oral delivery and
blood brain barrier (BBB) delivery. The successful delivery
of an orally administered drug to the systemic circulation is a
very complex issue. Several strategies to overcome the
barriers related to oral drug delivery including the use of
solubility enhancers (18), permeation enhancers (19), enzyme
inhibitors (20), mucoadhesive drug delivery systems or micro-
and nanoparticulate drug delivery systems have been inves-
tigated and are still of enormous interest for pharmaceutical
technologists (21,22). In recent years, it has been demon-
strated that improved oral bioavailability of efflux pump
substrates can be achieved by co-administration of efflux
pump inhibitors (23,24). Another interesting application of
efflux pump inhibitors combining oral drug delivery and
cancer therapy might be the local treatment of gastro-
intestinal carcinoma. The BBB significantly restricts the
delivery of certain drugs to the brain. Besides the brain
microvessel endothelial cells, that form tight extracellular
junctions and have low pinocytic activity, efflux transporters
that remove drugs from the epithelial cells are responsible for
the limited transport (25). An improved transport of efflux
pump substrates over the blood brain barrier can be achieved
by inhibiting BBB located efflux pumps (26).
In general, efflux pump inhibitors can be divided in
small molecule inhibitors (SMIs) and polymeric inhibitors.
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such as quinine or verapamil that are used in other clinical
indications and which were found to additionally inhibit
efflux pumps (27,28). Second and third generation SMIs such
as PSC833, GF120918 or KR30031 have been developed to
exclusively inhibit efflux pumps and to avoid further phar-
macological interactions (23,29,30). However, co-administra-
tion of SMIs commonly bears the risk of SMI mediated
toxicity, accumulation or anti-targeting. In recent years, some
widely used safe and so far believed pharmacological inactive
polymeric pharmaceutical excipients including Tween\ 80
and pluronic\ P85 have been identified to inhibit efflux
pumps (31,32). The beneficial effect of such polymers in
cancer therapy and drug delivery has been demonstrated by
various in vitro and in vivo studies. Regarding polymer
source, it can be distinguished between natural and synthetic
polymers. Within the current review, so far investigated
polymeric efflux pumps inhibitors and their use in cancer
therapy as well as in drug delivery will be discussed.
NATURAL POLYMERIC EFFLUX PUMP INHIBITORS
Various efflux pump inhibitory compounds occur in na-
ture. It has been demonstrated for example that polyphenols
of green tea and compounds of grapefruit juice can inhibit
efflux pumps (33, 34). Naturally occurring polymers include
polysaccharides, polypeptides and proteins. Polysaccharides
are the most frequently used group of natural polymers in
pharmaceutical compositions. Among them are polymers
such as starch, cellulose, hyaluronic acid and the chitin
derived chitosan. Although extensive literature review has
been performed, not much evidence for an efflux pump
inhibitory activity of any of these polymers could be found.
However, there is data available that supports the hypothesis
that polysaccharides can inhibit efflux pumps. Carreno-
Gomez and Duncan filed a patent, which covers the use of
polysaccharides, surfactants and dendrimers as efflux pump
inhibitors for the oral delivery of antitumor, antineoplastic,
antibiotic, antiviral, antifungal and antidepressant drugs.
Polysaccharides comprising D-mannosyluronic acid, L-gulosyluric
acid, D-glucose and/or D-glucuronic acid as well as D-mamose,
D-mannuronic acid and/or D-mannose monomers are pro-
tected by the invention. Furthermore, the patent includes all
polysaccharides comprising the monomers listed above with
carboxylic groups. Experimental data that proofs the efficacy
of dextran, anionic gums as well as sodium alginates to inhibit
efflux pumps is provided within the patent (35).
Anionic Gums
Representatives of natural gum polysaccharides include
agar, gellan gum, gum arabic, gum traganth, guar gum,
carrageenan and xanthan. Xanthan gum and gellan gum are
both used as food additives. Xanthan gum is produced by a
process involving fermentation of glucose or sucrose by the
Xanthomonas campestris bacterium. Gellan gum is produced
by the bacterium Sphingomonas elodea. The structures of
xanthan gum and gellan gum are presented in Fig. 1. The
effect of 0.5 mg/ml xanthan gum was evaluated with the
everted gut sac method and it was shown that in the presence
of xanthan gum the accumulation of the P-gp substrates
vinblastin and doxorubicin in the gut cells was increased. An
enhanced serosal transport of vinblastin but not of doxoru-
bicin was observed (35). Also the potential efflux pump
inhibitory activity of gellan gum was investigated. It could be
demonstrated that at a concentration of 0.5 mg/ml gellan gum
the serosal transport of vinblastin was improved, whereas the
tissue level remained unchanged. At the same concentration,
gellan gum improved the accumulation and the serosal
transport of doxorubicin (35).
Sodium Alginate
Alginates are linear copolymers with blocks of (1–4)-
linked b-D-mannuronate (M) and a-L-guluronate (G). The
monomers can appear in consecutive G-residues (G-blocks),
consecutive M-residues (M-blocks), alternating M and G-
residues (MG-blocks) or randomly organized blocks (Fig. 2).
Representatives which have been evaluated regarding efflux
pump inhibition are flavicam and ascophyllum. Flavicam is
gained from Lessonia flavicams. In studies with everted gut
sac cells, 0.5 mg/ml flavicam increased the accumulation of
doxorubicin in the cells as well as the serosal transport of the
drug, whereas no effect on vinblastin accumulation could be
observed (35). Ascophyllum is extracted from Ascophyllum
nodosum. Ascophyllum, at a concentration of 0.5 mg/ml,
increased vinblastin and doxorubicin accumulation in everted
gut sac cells. Furthermore the serosal transport of vinblastin
was enhanced, whereas the serosal transport of doxorubicin
could not be improved. Moreover, the effect of 250 mg/kg
ascophyllum on the biodistribution of radioactive labelled
vinblastin after oral gavage in rats was investigated. The
vinblastin blood level increased 1.7-fold in comparison to the
control (35). Besides the discussed polysaccharides, also
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Fig. 1. Chemical structure of anionic gums: a gellan gum, b xanthan gum
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the concentrations used (35).
SYNTHETIC POLYMERIC EFFLUX PUMP
INHIBITORS
A broad variety of synthetic polymers are used in
pharmaceutical applications. Historically, they have been
used as auxiliary agents in formulations where any pharma-
cological effect of the auxiliary agent is undesirable. However,
nowadays some interactions of such polymers with (patho)-
physiological processes are known to contribute to an
improved action of the drug formulation. Naturally derived
polymers such as chitosan can, for example, improve drug
permeation through biological membranes via an opening of
tight junctions. Synthetic polymers based on such polymeric
backbones often exhibit improved features (36). Besides
modifications of natural polymers, novel polymers can be
synthesised via polymerization of monomers. Synthetic
polymers used in pharmaceutical applications can also be
produced via coupling of a synthetic polymer such as
polyethylene glycol (PEG) to naturally occurring substances
such as fatty acids. It has been shown previously, that various
widely used synthetic polymeric pharmaceutical agents can
inhibit efflux pumps. Among them are polyethylene glycols
and PEG based detergents, copolymers such as poloxamers,
dendritic polymers and thiolated polymers.
Polyethylene Glycol
Polyethylene glycols [PEG; a.k.a. polyethylene oxide
(PEO) glycol and polyoxyethylene (POE) glycol] are poly-
mers produced via polymerization of ethylene oxide mole-
cules. Depending on their molecular weight, PEGs are
liquids or low-melting solids. Johnson et al. showed that
concentrations of 1–20% of PEG 400 significantly decreased
the basolateral to apical transport of digoxin through stripped
rat jejunal mucosa, indicating efflux pump inhibition (37).
Shen et al. investigated the potential of PEG 400, 2000 and
20,000 regarding efflux pump inhibition. They showed in
experiments with diffusion chambers and isolated rat intes-
tine that the secretory transport of rhodamine 123 was
inhibited by the addition of different concentrations (0.1–
20% v/v or w/v) of PEGs, irrespective of their molecular
weight (38). Additionally, they demonstrated in in situ closed
loop studies, that the absorption of rhodamine 123 was
improved when formulated in solutions containing different
concentrations of PEG 20,000. It could be demonstrated by
Hugger et al., that the permeation of efflux pump substrates
such as doxorubicin and paclitaxel through Caco-2 mono-
layers was improved in the presence of PEG 300. A
concentration dependent effect of PEG 300 on paclitaxel
transport was observed. Apical to basolateral transport
increased by using increasing concentrations of PEG 300,
whereas basolateral to apical transport decreased according-
ly. It was concluded that the efflux pump inhibition
mechanism of PEG 300 was mediated by changes in the
microenvironment of Caco-2 cell membranes (39). These
changes are probably related to modifications in the fluidity
of the polar head group regions of cell membranes. Further-
more, the same research group investigated the potential of
PEG 300 in MDR1 transfected Madin Darby Canine Kidney
(MDR1-MDCK) cell lines. PEG 300 (20%, v/v) caused
almost complete P-gp inhibition in Caco-2 and MDR1-
MDCK cells, whereas Cremophor\ EL (0.1%, w/v) and
Tween\ 80 (0.05%, w/v) only partially inhibited P-gp activity
in Caco-2 cells and turned out to be inactive as P-gp
inhibitors in MDR1-MDCK cell monolayers (40). Further-
more, an increased uptake of PEGylated paclitaxel in
comparison to unmodified paclitaxel after oral administra-
tion was observed. It was concluded that the water soluble
PEGylated prodrug was able to partly bypass P-glycoprotein
efflux and CYP3A metabolism, which might explain the
significantly improved absorption (41).
PEG Based Detergents
It has been demonstrated that various polymeric surfac-
tants including D-alpha-tocopheryl poly(ethylene glycol)
succinate 1000, polysorbates as well as POE stearates and
alkyl-PEO surfactants are capable of inhibiting efflux pumps.
Although only parts of their chemical structure have
polymeric character and their molecular mass is typically
below 2,000 Da, the most important representatives are
introduced below. Exemplarily, the structures of Tween\
80 and TPGS 1000 are shown in Fig. 3.
D-Alpha-Tocopheryl Poly(ethylene glycol) Succinate 1000
This compound has been used as a solubilising agent, an
emulsifier and in lipid based drug delivery. TPGS 1000 is
comprised of a hydrophilic head and a lipophilic alkyl tail.
Varma and Panchnagula recently demonstrated that TPGS
1000 can improve the oral bioavailability of the BCS class IV
drug and P-gp substrate paclitaxel and that this effect is
mediated by an improved drug solubility and P-glycoprotein
inhibition. A formulation containing 25 mg/kg paclitaxel and
50 mg/kg TPGS 1000 improved the oral bioavailability in rats
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Fig. 2. Chemical structure of alginates; consecutive M-residues
(MMM), consecutive G-residues (GGG), alternating M and G-
residues (MGM)
502 Werleabout sixfold, leading to an oral bioavailability of about 30%
(18). The paclitaxel plasma levels after oral administration of
the TPGS 1000 formulation in comparison to paclitaxel alone
are shown in Fig. 4. To gain more information regarding the
mechanism of TPGS 1000 mediated efflux pump inhibition,
the research group of Lehr investigated the influence of the
length of the alkyl-chain of various TPGS derivatives on their
efflux pump inhibitory activity. Results of ten different TPGS
derivatives ranging from TPGS 200–6000 revealed that the
commercially available derivative TPGS 1000 is the so far
most potent efflux pump inhibitor. However, according to a
Weinbull-distribution, promising TPGS derivatives may be
found in the range between TPGS 1100 and TPGS 1500 (42).
Polysorbates
Polysorbates are PEGylated sorbitanes esterified with
fatty acid. They are usually known under the brand name
Tween\. Most important regarding efflux pump inhibition are
polyoxyethylene sorbitan monolaurates (Tween\ 20), poly-
oxyethylene sorbitan monopalmitates (Tween\ 40) and poly-
oxyethylene sorbitan monooleates (Tween\ 80). Various
studies demonstrate the ability of Tweens\ to inhibit efflux
pumps. In 1990, Friche et al. observed an increased accumu-
lation of daunorubicin in resistant Ehrlich ascites tumor cells
in the presence of 0.01% (v/v) Tween\ 80 (31). In another
study, the efflux ratio (basolateral to apical drug transport/
apical to basolateral drug transport) was reduced in the
presence of Tween\ 80, when using the P-gp model drug
Rhodamine 123 and diffusion chambers with excised rat intes-
tinal mucosa (43). Various other studies further demonstrate
the efficacy of polysorbates to inhibit efflux pumps (44–46).
POE Stearates (Myrj\) and Alkyl-PEO Surfactants (Brij\)
Some studies support the theory that POE stearates
(commonly known as Myrj\) and alkyl-PEO surfactants
(commonly known as Brij\) can inhibit efflux pumps. The
oral bioavailability of the P-gp substrate cyclosporine A
administered in a solid dispersion of polyoxyethylene 40
stearate (Myrj\ 52) was in the same range as the oral
bioavailability of the commercial product Sandimmune Neoral
(47). If this effect was mediated only by drug solubilisation or
by efflux pump inhibition was not investigated in the study.
Lo demonstrated an improved intercellular accumulation of
epirubicin in the presence of polyoxyethylene 40 stearate
using Caco-2 cells. Moreover, the apical to basolateral
transport of epirubicin through Caco-2 cell layers increased
in presence of polyoxyethylene 40 stearate, whereas the
basolateral to apical transport decreased. These results
indicate polyoxyethylene 40 stearate mediated efflux pump
inhibition (44). Similar results were gained when using
polyoxyethylene laurylether (Brij\ 30). In another study,
conducted by Fo ¨ger et al., tablets based on polyoxyethylene
40 stearate containing the P-gp substrate rhodamine 123
increased the oral bioavailability in rats about 2.4-fold (48).
The results of this study, showing also the effect of other
polymeric efflux pump inhibitors are shown in Fig. 5.
Poloxamers
Poloxamers are widely known under the brand name
Pluronics\. Pluronic\ block copolymers consist of ethylene
oxide (EO) and propylene oxide (PO) segments arranged in
the basic A-B-A structure (Fig. 6). Therefore, Pluronics\ are
amphiphilic copolymers whose size and hydrophilicity/lip-
ophilicity can be varied by using different chain lengths of
EO and PO. Pluronics\ are so called Bfunctional excipients,^
which can affect immune response and wound healing (49,
50). A modulation of MDR related processes mediated by
Pluronics\ has been demonstrated the first time more than
10 years ago (32). Pluronic\ P85, which has been studied
extensively in terms of efflux pump inhibition, has a
molecular mass of about 4,600 Da. The efflux pump
inhibitory activity of Pluronics\ is used in two main areas:
(1) blood brain barrier (BBB) drug delivery and (2) cancer
therapy. The efflux pump inhibitory mechanism is believed to
be due to (a) Pluronic\ mediated ATPase inhibition and
ATP depletion and (b) effects of Pluronics\ on membrane
fluidization (51). It has been proven that the effect of
Pluronics\ on energy conservation is mediated by single
chain units (unimers). Experiments revealed that the inhib-
itory effect decreases when reaching the critical micelle
concentration (52). Regarding membrane fluidization, a
change in the membrane microviscosity using a hydrophobic
membrane probe was observed (51). Apart from Pluronics\,
another copolymer, CRL-1605 has already been used to
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Fig. 4. Plasma curves of paclitaxel (ng/ml) in rats after oral adminis-
tration of 25 mg/kg paclitaxel (open circle) and in combination with
50 mg/kg TPGS 1000 (filled circle). Figure adapted from (18)
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amikacin via P-gp inhibition (24,53).
Poloxamers for BBB Delivery
An excellent review article focussing on the role of
Pluronics\ in the delivery of efflux pump substrates through
the BBB as well as discussing the mechanisms of Pluronic\
mediated efflux pump inhibition has been published among
others by the pioneers in the field of Pluronic\ efflux pump
interactions, Kabanov et al. (54). The first study focussing on
the efflux pump modulating effect of Pluronics\ in the BBB
was published by Miller et al. (52). In this study, a concentra-
tion dependent inhibitory activity of Pluronic\ P85 was
observed by monitoring the accumulation of rhodamine 123
in brain microvessel endothelial cell (BMVEC) monolayers.
Nowadays, a multitude of data demonstrating the efficacy of
Pluronics\ for BBB delivery is available. In vitro permeation
studies using bovine brain microvessel endothelial cells
(BBMEC) and a broad variety of efflux pump substrates
including e.g., etoposide, doxorubicin and paclitaxel showed
an improved apical to basolateral drug transport (55). In
Table I, the permeation enhancement ratios of various efflux
pump substrates in the presence of Pluronic\ P85 using
BBMEC monolayers are summarized. Moreover, data that
demonstrate the in vivo efficacy of Pluronics\ to improve
BBB transport of efflux pump substrates are available. In one
study, the brain accumulation of digoxin in wild type mice,
mdr1a knockout mice and wild type mice treated with
Pluronic\ P85 was investigated. It could be demonstrated
that Pluronic\ P85 prolonged the residence time and
increased the concentration of digoxin in the brain (26).
Poloxamers in Cancer Therapy
The role of Pluronics\ in cancer therapy has been
comprehensively reviewed (56). Generally, polymeric exci-
pients have been used in cancer therapy to overcome MDR
by two different approaches: either by circumventing efflux
pump transport or by inhibiting efflux transporter proteins.
Kopecek et al. demonstrated that doxorubicin-HPMA [N-(2-
hydroxypropyl)methacrylamide] conjugate is transported via
a different mechanism than the free drug. The conjugate is
most likely transported in the cells via endocytosis, which
represents a P-gp independet pathway, whereas the free drug
is transported via membrane diffusion, a pathway which is
affected by efflux pumps (57,58).
Pluronic\ formulated doxorubicin has been evaluated to
be efficient in vivo in the treatment of various different kinds
of cancer (59). One mechanism, which is responsible for the
enhanced cytotoxicty of anticancer agents in the presence of
Pluronics\, is P-gp inhibition. It has been demonstrated in
vitro that there is an enhanced doxorubicin accumulation in
P-gp expressing cells in the presence of Pluronics\. Contrary,
this effect could not be observed when using non P-gp
expressing cell lines (60,61). These findings could be further
supported by studies of Evers et al. and Batrakova et al. who
showed that the accumulation and permeation of various P-gp
substrates was enhanced in the presence of Pluronics\ when
using MDR1 transfected cells, whereas no or only little
effects could be observed in non-transfected cells (26,62).
Also no enhanced accumulation of non-P-gp substrates in
neither resistant nor sensitive cells could be observed (26,52,
63). Moreover there is evidence that Pluronics\ can inhibit
other efflux pumps such as MRP1 and MRP2. However, the
effect of Pluronics\ on P-gp ATPase activity is considerably
greater compared with the effects on MRP1 and MRP2
ATPases (64). This hypothesis is supported by the data
presented in Table I. Generally, the enhancement ratio of P-gp
substrates or P-gp/MRP substrates tends to be higher in
comparison to the enhancement ratio of MRP substrates.
Besides efflux pump inhibition, Pluronics\ are promising
agents in cancer therapy because they affect drug sequestra-
tion and the GSH/GST detoxification system. The impor-
tance of these mechanisms and the beneficial effect of
Pluronics\ on them have been summarized previously (56).
Dendrimers
Dendrimers (dendritic polymers) are fully synthetic
macromolecules with a defined structure. From a core
located in the center of the dendrimer, branched repeat units
emanate. The surface can display functional groups such as
primary amines or hydroxyl groups. Exemplarily, the struc-
ture of a polyamidoamine (PAMAM) dendrimer is shown in
Fig. 7. The first dendrimers have been described nearly 30
years ago (65). Dendrimers are used as delivery systems for
potent anticancer drugs (66), in gene delivery and in imaging
(67,68). There is some evidence that dendrimers might be
interesting tools for the delivery of efflux pumps substrates.
D_Emanuele et al. showed that the conjugation of the P-gp
substrate propranolol to generation 3 (G3) and lauroyl-G3
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Fig. 6. Chemical structures of poloxamers (Pluronics\)
504 WerlePAMAM dendrimers improved apical to basolateral trans-
port and decreased basolateral to apical transport through
Caco-2 monolayers. The mechanism responsible for this
behaviour was attributed to a circumvention of P-gp trans-
port rather than to P-gp inhibition, because in the presence of
the well known P-gp inhibitor cyclosporine A, no further
improvement of propranolol transport was observed (69).
However, it has been shown that the transport of efflux pump
substrates in the presence of dendrimers was improved
without conjugating the substrate to the dendrimer. The
accumulation of vinblastine and doxorubicin using gut sacs
was improved about three- and fourfold in the presence of a
G3 dendrimer. These results might indicate a possible efflux
pump inhibition (35).
Thiomers
Thiolated polymers, or so called Bthiomers^ have been
recently introduced in the pharmaceutical arena. Thiomers
are multifunctional polymers used in buccal, nasal, ocular,
oral and vaginal delivery. It has been demonstrated that the
introduction of thiol groups on polymers can lead to
Table I. Effect of Pluronic\ P85 on the Permeability of Various
Efflux Pump Substrates Through Brain Microvessel Endothelial Cell
(BMVEC) Monolayers
Efflux Pump Substrate Efflux Pump
Enhancement
Ratio
Methotrexate MRP 1.3
Fluorescein MRP 1.5
Rhodamine 123 P-gp 1.6
Zidovudin MRP 2.0
Doxorubicin P-gp, MRP 2.4
Digoxin P-gp 4.1
Ritonavir P-gp 7.7
Paclitaxel P-gp 11.2
Vinblastin P-gp, MRP 19.0
Enhancement ratio=apical to basolateral substrate transport in the
presence of P85/apical to basolateral substrate transport in buffer;
table adapted from (54).
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505 Natural and Synthetic Polymers as Inhibitors of Drug Efflux Pumpsimproved mucadhesive, cohesive, enzyme inhibitory and
permeation enhancing properties (70). The chemical struc-
ture of two widely used thiomers is provided in Fig. 8.
Recently, it has been demonstrated that thiomers can inhibit
efflux pumps (71). No data regarding the efflux pump
inhibitory activity of unmodified chitosan, which often serves
as polymeric backbone of thiomers, could be found. Also for
unmodified polyacrylates, which represent another group of
polymeric backbones used for thiomer synthesis, no data
demonstrating an eventual efflux pump inhibitory effect is
available. The use of carbopol, a crosslinked poly(acrylic)acid
derivative—which is known to enhance the paracellular uptake
of hydrophilic drugs via an opening of tight junctions mediated
by calcium complexation (72–74)—did not lead to a pro-
nounced improved cell accumulation of the efflux pump
substrate doxorubicin in flow cytometry studies (enhancement
factor 1.15T0.04) (75). Therefore, it is most likely that the
efflux pump inhibitory activity of thiomers is mediated by the
introduced thiol groups.
In studies with the P-gp substrate Rhodamine 123 it has
been demonstrated that the thiomer chitosan–thiobutylami-
dine (chito–TBA) improves apical to basolateral substrate
transport through excised guinea pig ileal mucosa and
furthermore decreases basolateral to apical substrate trans-
port. This effect was even more pronounced when using a
combination of chito–TBA and glutathione (GSH) (71).
Fo ¨ger et al. showed that oral administration of tablets
containing a combination of chito–TBA and GSH led to
significantly improved Rhodamine 123 plasma levels in rats
in comparison to tablets based on either poloxamer or Myrj\
(48,76). The results are shown in Fig. 5. An improved uptake
of the efflux pump substrate, saquinavir, in presence of a
thiomer/GSH system has also already been demonstrated
(77). Studies demonstrating an improved uptake of paclitaxel
after oral administration in a thiomer delivery system are
currently under review. Moreover, it has been demonstrated
that the transepithelial transport of sulforhodamine 101,
representing a MRP2 substrate, in the absorptive direction
was improved up to about 4.5-fold in presence of 0.5% (m/v)
thiolated poly(acrylic acid) of various molecular mass (78).
These findings seem to indicate that thiomers might be useful
tools to deliver various drugs which are affected by efflux
transporters such as P-gp and MRP.
DISCUSSION
Various polymeric agents are nowadays known to inhibit
effluxpumps.They gained attentionin different research fields,
including cancer therapy and drug delivery. In Table II, efflux
pump substrates that have been used so far in connection with
polymeric efflux pump inhibitors are summarized. The classi-
fication regarding application is based on the used cell-lines
(BBMEC monolayers, healthy intestinal tissue, Caco-2 mono-
layers and other cancer cell-lines) or animals (tumour bearing,
healthy) and on the substrate (anticancer drug, other drug/
substrate). Efflux pumps substrates listed in the subdivision
Bcancer therapy^ are anticancer drugs that have been used in
studies using cancer cell-lines or tumour bearing animals.
Efflux pump inhibition can be mediated by numerous
mechanisms. Especially SMIs are capable of inhibiting efflux
pump by blocking or modifying efflux pump drug-binding
sites (79). However, efflux pumps display various drug-
binding sites, so that a targeted development of SMIs
inhibitors remains difficult. There is controversy about the
exact number and nature of efflux pump drug binding sites.
Up to four distinct and partially overlapping drug-binding
sites for P-gp have been identified so far (80–83). According
to another hypothesis, P-gp has a Bcommon drug-binding
site,^ and the binding of structurally diverse substrates can be
explained by a Bsubstrate induced fit,^ in which the substrates
create their own drug-binding sites within the area circled by
the transmembrane domains (TMD) 4–6 and 9–12 (84,85). So
far developed structure activity relation (SAR) models are
either based on ligands or on homologue models, because
high resolution X-ray structures of the transporter proteins
are not available yet (86–88). A target-oriented design of
polymeric efflux pump inhibitors is even more challenging
and intrinsic in comparison to the design of SMIs, because
additional factors including unspecific interactions with the
cell membrane might be responsible for efflux pump
inhibition. In Fig. 9, the possible interactions of polymers
and efflux pumps are schematically presented. The mecha-
nism of polymeric inhibitors often seems to be mediated by
altering the integrity of cell membrane lipids (Fig. 9b). This
mechanism is most likely responsible for the inhibitory
activity of PEG and of polymers that do not access the cells,
like polysaccharides and thiomers. For thiomers, also a
mechanism based on the formation of disulfide bonds
between the free thiol groups of the thiomers and cysteine
of P-gp inside of the transporter channel has been suggested
(Fig. 9e). Especially an interaction of thiomers with the
channel-forming transmembrane domains of P-gp has been
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Fig. 8. Structure of thiomers: a chitosan–thiobutylamidine (chito–
TBA), b poly(acrylic acid)-cysteine (PAA-Cys)
506 Werlediscussed (89), because two of the regions, namely 2 and 11,
exhibit cysteine subunits on position 137 and 956. However,
no experimental data backing up this theory is currently
available. In contrast, for amphiphilic compounds such as
poloxamers, there is experimental evidence that shows that
membrane alterations are at least partly responsible for efflux
pump inhibition. It has been demonstrated that membrane
fluidization mediated by pluronics leads to a decrease of the
ATPase activity (Fig. 9b) (51). Moreover, the poloxamer
unimers inhibit efflux pumps also via intercellular interactions,
especially by interfering with ATP related mechanisms such as
ATP depletion (Fig. 9a) (51). Therefore, similar mechanisms
as described for poloxamers might be responsible for other
amphipilic compounds such as Myrj\ and Brij\. Interestingly,
it was demonstrated recently by the research group of Lehr,
that the efflux pump inhibitory activity of TPGS 1000 is not
mediated by membrane fluidization. Membrane fluidization
was observed at concentrations 100-fold higher than necessary
for P-gp inhibition. A modulation of the ATPase activity
correlated with the inhibitory potential, which leads to the
conclusion that ATPase inhibition is mainly responsible for the
inhibitory activity of TPGS (Fig. 9d) (90). The inhibitory
mechanism of dendrimers has not been evaluated so far. It has
been demonstrated, that dendrimers are transported into the
cells via endocytosis (91). Therefore, efflux pump inhibition
mediated by ATP-depletion, ATPase inhibition or alteration
of the cell membranes seem to be possible explanations. Due
to the rigid structure of dendrimers, blocking of substrate
binding-sites seems rather unlikely, although this possibility
cannot be excluded. Moreover, it is not completely clear yet, if
the effect of dendrimers regarding efflux pump substrate
transport is really based on inhibitory mechanisms or on
bypassing efflux transporters (Fig. 9c). It has been demon-
strated by Kopecek et al., that drug-polymer conjugates can
bypass P-gp mediated transport (57,58). Especially regarding
amphiphilic compounds, other possible mechanisms apart
from efflux pump inhibition that can lead to an improved oral
drug bioavailability or changes in pharmacokinetics must be
taken into consideration. Most important in this context are
permeation enhancing effects mediated by interactions with
the cell membranes and drug solubilising effects of such
compounds.
Table II. Efflux Pump Substrates, Polymeric Efflux Pump Inhibitors and the According Application Thereof
Efflux Pump Substrate Polymeric Inhibitor Application Reference
3¶-azido-3¶deoxythimidine Pluronic\ P85 BBB delivery (55)
Digoxin (26, 54)
Doxorubicin (55)
Etoposide (55)
Fluorescein (55, 60)
Loperamid (55)
Methotrexate (54)
Paclitaxel (60)
Rhodamine 123 (52, 60)
Ritonavir (54)
Valproic acid (55)
Vinblastin (54)
Zodovudin (60)
Daunorubicin Tween\ 80 Cancer therapy (31)
Doxorubicin Pluronic\ L61/Pluronic\ F127 (59)
Epirubicin Brij\ 30, Tween\ 20, Tween\ 80,
Myrj\ 52
(44)
Amikacin CRL-1605 Oral delivery (53)
Cyclosporin A Myrj\ 52 (47)
Digoxin PEG 400, Tween\ 80 (37, 45)
Doxorubicin Anionic gums, alginates (35)
Epirubicin Brij\ 30, Tween\ 20, Tween\ 80,
Myrj\ 52
(44)
Paclitaxel TPGS 1000 (18)
Rhodamine 123 Chito–TBA (48, 71, 76)
PEG 400, PEG 2,000, PEG 20,000,
TPGS 200, TPGS 238, TPGS 400, TPGS 600,
TPGS 1000
(38)
TPGS 2000, TPGS 3400, TPGS 3500, TPGS 4000,
TPGS 6000
(18)
TPGS 1000 (46)
Tween\ 80 (43, 46)
Myrj\ 52 (48)
Saquinavir Chito–TBA (77)
Sulforhodamine 101 Poly(acrylic acid) cysteine (78)
Tobramycin CRL-1605 (24)
Vinblastin Anionic gums, alginates (35)
507 Natural and Synthetic Polymers as Inhibitors of Drug Efflux PumpsWhen choosing a polymeric efflux pump inhibitor for a
certain application, several points have to be considered. One
important factor is definitely the concentration of the
auxiliary agent. In Table III, polymeric inhibitors, the cell-
type used for the investigations, the involved efflux pumps as
well as the effective concentration/s are summarized. Con-
centrations ranging from 0.001% [Pluronic\ P85; (52)] up to
20% [PEGs; (38)] have been evaluated to be effective in
vitro. In comparison to the mostly lipophilic and well
absorbed SMIs (92), many orally administered polymeric
auxiliary agents are not absorbed and therefore systemic
mediated toxicity or side effects can be minimised or even
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Fig. 9. Schematic presentation of interactions between polymeric efflux pump inhibitors and efflux pumps; polymer ($$$), ATP (triangle),
drug (square); a inhibition mediated by ATP depletion, b inhibition mediated by interactions with the membrane, c bypassing drug efflux by a
drug-polymer conjugate, d inhibition mediated by interfering with ATP-binding sites and e blocking of drug binding sites or other sites within
the trans-membrane domains (TMB)
Table III. Polymeric Efflux Pump Inhibitors, Tested Cell Types, Inhibited Transporters and Effective Polymer Concentration
Polymer Cell Type Transporter Effective Concentration (%) Literature
Xanthan gum Rat intestine P-gp 0.05 (35)
Gellan gum Rat intestine P-gp 0.05 (35)
Flavicam Rat intestine P-gp 0.05 (35)
Ascophyllum Rat intestine P-gp 0.05 (35)
Dextran Rat intestine P-gp 0.05–0.1 (35)
PEG 300 Caco-2, MDCK-MDR1 P-gp 20 (39, 40)
PEG 400, 2,000, 20,000 Rat intestine P-gp 0.1–20 (37, 38)
TPGS 1000 Caco-2 P-gp 0.0038 (46)
TPGS 200–6000 Caco-2 P-gp 0.005 (42)
Tween 80 Ehrlich ascites tumor cells,
rat intestine, Caco-2
P-gp, MRP1 <0.13 (31, 46)
Myrj 52 Rat intestine P-gp 0.5 (48)
Pluronic P85 BBMEC P-gp, MRP 0.001–1 (52, 55)
PAMAM G3, G3.5 dendrimer Rat intestine P-gp 0.05 (35)
Chito–TBA Guinea pig intestine, rat intestine,
Caco-2
P-gp 0.25–0.5 (71, 76, 77)
PAA-Cys (PAA 2, 100, 250, 450,
3000 kDa)
Rat intestine MRP2 0.5 (78)
508 Werleexcluded (93,94). This renders polymeric efflux pump inhib-
itors an interesting tool for oral drug delivery. Representa-
tives of this group of polymeric inhibitors are polysaccharides
as well as thiomers. Another advantage of such high
molecular mass inhibitors is that the drug can be embedded
in the polymeric matrix. A controlled release allows that the
drug is liberated at the same intestinal tissues as the efflux
pump inhibition takes place. However, SMIs might be the
better option when further systemic efflux pump inhibition is
intended. Due to the absorption of SMIs, systemic inhibitory
effects might e.g., facilitate additionally improved BBB
delivery. Dendrimers and Pluronics\ have so far not gained
too much attention for oral drug delivery, however, they
might be promising candidates too. Regarding BBB delivery
and cancer therapy, most studies have been conducted with
block copolymers. The big advantage of such polymers in
comparison to other polymers discussed in the current review
is that there is much data available that proofs their safety.
RheothRx, a clinical form of Pluronic\ F68 for the treatment
of myocardial infarction was well tolerated in human trials at
cumulative doses as high as 2.2 g/kg infused over 24 h (95).
Although the formulation was withdrawn from phase III
trials because of toxic concerns, it must be mentioned that
the toxicity was rather mediated by impurities than by the
poloxamer itself (96). Other studies conducted in rodents and
non-rodents showed, that the toxic dose was about 1.0–1.3 g/kg,
which is about 30 times higher than the concentration intended
for a use in human volunteers (97,98).
CONCLUSION
Up to date, the potential of various structural diverse
polymeric compounds to inhibit efflux pumps has been demon-
strated. In addition, their efficacy in cancer therapy as well as
drug delivery could be shown. Especially the use of poloxamers
in cancer therapy and BBB delivery is very promising and
sufficient data—also of clinical trials—are available. Another
emerging research field is the use of polymeric efflux pump
inhibitors in oral drug delivery. There are various mechanisms
that can be responsible for polymeric efflux pump inhibition,
including membrane fluidization, ATP depletion and interac-
tion with drug- or ATP-binding sites.Forsomepolymerssuch as
dendrimers, the mechanism/s still remain/s unclear. A better
understanding of the interaction between efflux pumps and
polymeric inhibitors would highly contribute to the develop-
ment of more specific and safe inhibitors.
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